At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
L-ornithine-L-aspartatedrug
Likely dose
L-ornithine-L-aspartate 30gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness of L-ornithine-L-aspartate on Plasma Ammonia in Cirrhotic Patients After TIPS Procedure: a Prospective, Randomized, Controlled, Open-label Clinical Trial
Air Force Military Medical University, China·interventional·Posted Sep 27, 2011·Updated Dec 19, 2012
In Brief
A Phase 3 clinical trial evaluating L-ornithine-L-aspartate for Decompensated Cirrhosis and 3 related conditions. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The aim of this study is to evaluate the effectiveness of L-ornithine-L-aspartate (LOLA) on plasma ammonia in cirrhotic patients after Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartDec 2011
Primary CompletionDec 2012
TodayJul 2026
First PostedSep 27, 2011
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.8 years ago
Interventions
L-ornithine-L-aspartatedrug
The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.